Introduction {#Sec1}
============

Glaucoma consistently ranks as one of the leading causes of all blindness worldwide and is the single biggest cause of irreversible blindness \[[@CR1], [@CR2]\]. Population estimates reveal formidable numbers of patients affected by glaucoma, with rates increasing as life expectancies lengthen. To prevent visual deterioration and optic nerve damage, patients and their doctors initiate treatment, the cornerstone of which is the reduction of intraocular pressure (IOP). Medications typically are the first line of treatment, although their effectiveness is limited by local and systemic side effects, ocular surface damage, cost, complex dosing regimens, and suboptimal patient adherence \[[@CR3]--[@CR11]\]. Laser trabeculoplasty often is completed alongside or after medications, although it induces inflammation and its IOP-lowering impact has a limited time frame \[[@CR12]\].

In later stages of the disease, traditional filtering surgeries such as tube shunt implantation or trabeculectomy are the main treatment modalities; however failure rates and long-term complications (e.g., endophthalmitis, hypotony, choroidal detachment, bleb leak, or infection) are a real concern \[[@CR13]--[@CR15]\]. If dramatic and immediate IOP reduction is needed, then these risks may be appropriate. However, for a large portion of the glaucoma population---particularly in eyes that need additional intervention beyond medication and/or lasers, but that do not yet warrant the risks of filtering surgery---a surgical treatment with a more favorable benefit-to-risk ratio may be preferable.

Micro-invasive glaucoma surgery (MIGS) offers such a treatment, as it has shown consistent reductions in IOP and medication burden, while also maintaining favorable long-term safety \[[@CR16]\]. A sizable body of evidence has shown that the eyes benefiting from this treatment can include those with more moderate and severe stages of glaucoma as well as mild glaucoma; and they may include eyes with newly diagnosed, treatment-naive glaucoma, in addition to those that already tried (and failed) prior medications and/or laser procedures.

The first MIGS implant was the iStent^®^ Trabecular Micro-Bypass (Glaukos Corp., San Clemente, CA, USA; FDA 2012, CE 2004). To date, this device has amassed a sizable long-term evidence base regarding its safety and performance in eyes with open-angle glaucoma, in settings both with and without cataract surgery. Most studies of the device have assessed outcomes in mild to moderate glaucoma \[[@CR17]--[@CR27]\], but other patient populations increasingly have been the subject of evaluation, such as pseudoexfoliative glaucoma, severe or refractory glaucoma, or newly diagnosed, treatment-naïve glaucoma \[[@CR28]--[@CR33]\]. Another growing and relevant area of investigation has been economics outcomes research \[[@CR34]--[@CR39]\], which consistently has shown favorable cost-effectiveness of the iStent in various healthcare models around the world.

The newest US FDA-approved device in the MIGS treatment area is the second-generation iStent *inject*^®^ Trabecular Micro-Bypass (Glaukos; FDA 2018, CE 2010), which includes two trabecular stents designed to reduce IOP by bolstering aqueous outflow through the trabecular meshwork into Schlemm's canal (Figs. [1](#Fig1){ref-type="fig"}--[2](#Fig2){ref-type="fig"}). In studies both with and without cataract surgery, and in both investigational and real-world settings, the *ab interno*-implanted iStent *inject* has demonstrated clinically significant reductions in IOP and medications over the long term \[[@CR40]--[@CR51]\]. These performance outcomes have been accompanied by favorable safety and a correspondingly advantageous benefit-to-risk profile.Fig. 1iStent *inject*^®^ and iStent *inject*^®^ Trabecular Micro-Bypass Stent System. Provided by Glaukos Corp.Fig. 2iStent *inject*^®^ implantation: placement of two stents in the anterior chamber angle. Provided by Glaukos Corp.

In the present prospective cohort, we evaluate whether stand-alone second-generation trabecular bypass stent implantation is a durable, effective, and safe method to reduce IOP and medications in glaucomatous eyes with a substantial preoperative disease burden. This intervention was completed by a single surgeon within a real-world clinical setting and with a relatively long period of follow-up, providing relevant data to doctors and patients evaluating their glaucoma treatment options.

Methods {#Sec2}
=======

Study Design {#Sec3}
------------

This prospective, non-randomized, consecutive case series included eyes with various types of glaucoma that underwent implantation of two second-generation trabecular micro-bypass stents as a stand-alone procedure. One surgeon (F.H.) completed all surgeries during a 39-month period at an academic ophthalmology center in Heidelberg, Germany. Subjects were required to have glaucoma \[including primary open-angle glaucoma (POAG), appositional narrow-angle glaucoma (NAG, defined as angle Shaffer grade 2, with an open angle in the area of stent implantation), pseudoexfoliative glaucoma (PXG), or secondary glaucoma\], to be eligible for iStent *inject* surgery, and to have experienced glaucoma progression despite prior medical and/or surgical glaucoma treatment. Exclusion criteria included active intraocular inflammation, corneal and/or media opacities preventing the gonioscopic view, angle closure in the area of stent implantation, pregnancy, age \< 18 years, or congenital glaucoma.

Effectiveness outcomes consisted of IOP (3 measurements per time point, measured by Goldmann applanation) and topical ocular hypotensive medications. Baseline IOP was determined by IOP readings at two or more preoperative visits. Safety outcomes included CDVA, intraoperative and postoperative adverse events, and secondary surgical interventions. During the follow-up period, testing included visual fields every 6 months, OCT RNFL every 12 months, and optic nerve examination at every visit. Further surgical procedures were considered if visual field, OCT, or optic nerve findings were concerning for glaucoma progression and/or if IOP was inadequately reduced by iStent *inject* surgery (per surgeon discretion).

All procedures performed were in accordance with the ethical standards of the institutional and/or national research committee \[the Institutional Review Board (IRB) of the University of Heidelberg\] and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study. No clinical trial registration was required for the study. Patients have been followed through 36 months postoperatively, and follow-up is ongoing.

Stent Description, Surgical Technique, and Perioperative Medication {#Sec4}
-------------------------------------------------------------------

iStent *inject* implantation was completed as a sole procedure (i.e., without cataract surgery), using the standard implantation technique described previously \[[@CR40], [@CR43], [@CR45]\]. In brief, the procedure consists of the following: after pupillary miosis and anterior chamber filling with a medium viscous ocular surgery viscoelastic device (OVD), the single-use, stainless steel injector is advanced through a temporal corneal incision to the nasal Schlemm's canal, where two pre-loaded titanium stents are implanted *ab interno* approximately two clock-hours apart (Figs. [1](#Fig1){ref-type="fig"}--[2](#Fig2){ref-type="fig"}). Each heparin-coated, 360 µm × 230-µm stent has a symmetric design (compatible with right or left eyes) and several lateral outlet lumens designed to decrease IOP by bolstering aqueous outflow from the anterior chamber to Schlemm's canal. OVD is removed by bimanual irrigation and aspiration. After surgery, patients received 1 week of topical antibiotic (ciprofloxacin) and 4 weeks of topical anti-inflammatory medication (dexamethasone).

Data analyses {#Sec5}
-------------

Descriptive statistics were used to summarize mean IOP and number of medications from the preoperative visit through 36 months postoperatively. Preoperative and 36-month proportional analyses were completed for percent of eyes with IOP ≤ 18 mmHg, IOP \< 15 mmHg, and ≥ 20% IOP reduction; eyes on 0, 1, 2, or ≥ 3 medications; and eyes with reduced medications versus preoperatively. A paired *t*-test was used to compare preoperative versus month 36 mean IOP and number of medications, and the McNemar test was used to compare preoperative and month 36 proportional IOP outcomes.

Results {#Sec6}
=======

Subject Accountability, Demographics, and Preoperative Parameters {#Sec7}
-----------------------------------------------------------------

A total of 44 consecutive eyes of 31 patients were evaluated in this cohort, with glaucoma diagnoses including POAG (*n* = 38), PXG (*n* = 4), appositional NAG (*n* = 1), and secondary (neovascular) glaucoma (*n* = 1)(Table [1](#Tab1){ref-type="table"}). Preoperative ocular parameters reflected a substantial disease burden. Mean medicated IOP was 25.3 ± 6.0 mmHg on a mean of 2.98 ± 0.88 medications, with 75% (33/44) of eyes on 3--5 glaucoma medications and no eyes medication-free. Average visual field mean deviation (VF MD) was -- 6.4 dB, and mean C:D ratio was 0.8, with 73% of eyes (32/44) having a C:D ratio ≥ 0.8. Half of the eyes (22/44) had undergone a total of 35 glaucoma surgeries prior to iStent*inject* implantation.Table 1Demographics and preoperative characteristics (*n* = 44 eyes of 31 patients)iStent *inject* (44 eyes)Gender M/F23/21Age (years)Mean ± SD (range)71.3 ± 10.5(40--88)Race100% Caucasian C:D ratio Mean ± SD (range)0.8 ± 0.1(0.5--1.0) VF MD (dB) Mean ± SD (range)-- 6.4 ± 6.9 dB(− 24.4 to − 0.3)Type of glaucoma *n* (%) POAG PXG38 (86.4%)4 (9.1%) Appositional narrow angle^a^1 (2.3%) Secondary (neovascular)1 (2.3%)Mean medicated IOP (mmHg); mean ± SD25.3 ± 6.0 mmHgMedicated IOP level (mmHg) *n* (%) ≤ 15 mmHg1 (2.3%) ≤ 18 mmHg4 (9.1%)Mean \# medications; mean ± SD2.98 ± 0.88Eyes with prior glaucoma surgery *n* (%)22 (50.0%)Prior glaucoma surgeries, *n* = 35 surgeries^b^ Trabeculectomy13 CPC14 ALT/SLT3 Laser iridotomy2 Single iStent1 XEN implantation2Eyes on 3--5 preoperative medications, *n* (%)33 (75%)*SD* standard deviation, *C:D* cup to disc, *VF MD* visual field mean deviation, *CPC* cyclophotocoagulation, *ALT* argon laser trabeculoplasty, *SLT* selective laser trabeculoplasty^a^Eyes had open-angle configuration in the area of iStent *inject* implantation^b^Eyes could have more than one surgery (there were 35 surgeries in 22 eyes)

Intraocular Pressure and Medication Use {#Sec8}
---------------------------------------

At 36 months postoperatively, mean IOP reduced by 42% to 14.6 ± 2.0 mmHg (*p* \< 0.0001) (Fig. [3](#Fig3){ref-type="fig"}), with 87.9% of eyes (29/33) decreasing IOP by ≥ 20% versus preoperatively. Nearly all eyes (97.0% or 32/33) achieved month 36 IOP ≤ 18 mmHg versus 9.1% (4/44) preoperatively (*p* \< 0.0001) (Fig. [4](#Fig4){ref-type="fig"}), and 70.0% of eyes (23/33) achieved month 36 IOP ≤ 15 mmHg versus 2.3% (1/44) preoperatively (*p* \< 0.0001). Mean number of medications decreased by 82% to 0.55 ± 0.79 (*p* \< 0.0001)(Fig. [5](#Fig5){ref-type="fig"}). The per-patient medication impact at 36 months consisted of 61% of eyes (20/33) becoming medication-free (versus 0% preoperatively) and only 3.0% (1/33) on 3 medications versus 75% (33/44) on 3--5 medications preoperatively (Fig. [6](#Fig6){ref-type="fig"}). All eyes maintained or decreased their 36-month medication burden versus preoperatively.Fig. 3Reduction in mean intraocular pressure through 36 months (*p* \< 0.0001); eyes with available data at each visit. *IOP* intraocular pressure, *SD* standard deviation, *M* month, *Preop* preoperativeFig. 4Proportional analysis of eyes with IOP ≤ 18 mmHg and ≤ 15 mmHg through 36 months\*; eyes with available data at each visit. *IOP* intraocular pressure, *M* month, *Preop* preoperative. \*Highly significant (*p* \< 0.0001) increase in proportion of eyes with IOP ≤ 18 mmHg and IOP ≤ 15 mmHg at M36 vs. preoperativelyFig. 5Reduction in medication burden at 36 months vs. preoperative (*p* \< 0.0001); eyes with available data at each visit. *M* month, *Preop* preoperativeFig. 6Proportional analysis of medication use through 36 months; eyes with available data at each visit. *M* month, *Preop* preoperative, *Med* medication

Safety {#Sec9}
------

Successful implantation of two second-generation trabecular micro-bypass stents was completed in all eyes in this study. One eye had planned XEN explantation at the time of stent surgery, while all other eyes underwent stent implantation as a sole procedure. One intraoperative complication was reported, consisting of mild hyphema in the anterior chamber, which necessitated no intervention and resolved without sequelae by week 1.

Postoperatively, all but four eyes had CDVA of 20/50 or better throughout follow-up (26/26 eyes at 12 months, 21/21 eyes at 24 months, and 30/30 eyes at 36 months postoperatively). The four eyes with CDVA worse than 20/50 had preexisting poor CDVA (ranging from 20/63 to 20/20,000 Snellen equivalent preoperatively). Ocular adverse events through 36 months postoperatively included two eyes of the same patient that had cataract progression starting at month 3 (CDVA remained at 20/40 or better in both eyes through 36 months) and one eye with uveitis at 24 months, which resolved without sequelae with 3 weeks of topical anti-inflammatory medication. Two eyes underwent additional glaucoma procedures at 1 month postoperatively (XEN implant and cyclophotocoagulation, respectively) because of the need for additional IOP reduction beyond what was achieved with iStent *inject* implantation (IOP had reduced to 14 mmHg ad 22 mmHg in the two eyes, respectively). No other secondary glaucoma surgeries or ocular adverse events occurred for the remainder of follow-up. In particular, there were no reports of hypotony, endophthalmitis, corneal complications, myopic shift, stent obstruction, peripheral anterior synechiae (PAS), or choroidal detachment.

Discussion {#Sec10}
==========

Three-year data from this prospective real-world cohort demonstrated safe, sustained, clinically and statistically significant reductions in IOP and medications in eyes with glaucoma after stand-alone iStent *inject* implantation. The preoperative disease burden in this patient cohort was sizable, with three-fourths of eyes on three or more medications, half of eyes with a history of prior glaucoma surgery, and moderate glaucomatous damage per VF MD and C:D ratio. Despite medications and/or surgery, however, mean preoperative IOP was \> 25 mmHg, indicating the inability of such treatments to control the disease. It is noteworthy that iStent *inject* had a positive effect in these formerly treatment-resistant eyes. This treatment effect is consistent with prior studies showing benefit of this technology in various stages of glaucoma, from mild to advanced \[[@CR40]--[@CR51]\]. It also suggests that iStent *inject* may have a viable role in settings different from those typically considered for MIGS procedures: specifically, it may be considered not just in mild-to-moderate glaucoma as a primary surgery, but also in refractory eyes that have progressed despite previously undergoing more invasive surgery.

This study assessed stand-alone stent implantation, thereby allowing the device's treatment effects to be separated from those of phacoemulsification, which is known to reduce IOP to a modest degree in eyes with glaucoma \[[@CR52]--[@CR54]\]. Due to the stents alone, mean 36-month IOP showed a 42% decrease, a reduction consistent with those in previous studies of both combined and stand-alone iStent *inject* implantation \[[@CR40]--[@CR51]\]. The observation of comparable 36-month outcomes either with or without cataract surgery is not entirely surprising, since the IOP-reducing effect of cataract surgery is known to be temporary \[[@CR52]--[@CR54]\] and thus would be unlikely to persist through the month 36 visit.

Compared with the previously published outcomes of the surgeon's stent-cataract experience, in which IOP was reduced by 37% and medications were reduced by 68% \[[@CR46]\], the IOP and medication reductions in this stand-alone cohort were slightly higher (42% and 82% reductions, respectively). Possible reasons for this difference include the higher preoperative IOP in the stand-alone cohort, as this is known to produce greater postoperative IOP reductions \[[@CR27], [@CR29]\]. The preoperative medication burden also was higher in the stand-alone cohort, which may predispose to greater reductions in medication number if the end goal is the same for a given patient (0 or 1 medication, for example). The difference also may reflect the surgeon's learning curve, since the surgeon's first cases were mostly combination surgeries (iStent *inject* + phaco), whereas most of his stand-alone cases were completed later in his experience with the device.

A particularly meaningful end point is the significant increase in eyes achieving IOP ≤ 18 mmHg at 36 months (97.0% versus 9.1% preoperatively), as reaching this IOP threshold is known to be associated with a lessened visual field decline over the long term in patients with glaucoma \[[@CR55]\]. Coincident with this IOP decrease, mean medication burden was reduced by nearly 2.5 medications (82% reduction), and all eyes had maintained or reduced antihypertensive medications versus their preoperative regimen. While no eyes were medication-free preoperatively, a majority (61%) were off all drops by 36 months postoperatively. While three-fourths of eyes were on 3--5 medications preoperatively, only one eye (3.0%) was on 3 medications at 36 months postoperatively.

The benefits of medication reduction are myriad. It promotes treatment adherence, which has been shown to decrease dramatically when more than one eye drop is prescribed \[[@CR5]\]. The ability to be off topical medications altogether is particularly advantageous, as considerable evidence has shown these medications to have toxic and pro-inflammatory effects on ocular surface cells \[[@CR4], [@CR10]\]. Medication reduction lessens the financial burden of glaucoma treatment, for both patients and government bodies funding healthcare. This financial impact has been the area of several informative cost-effectiveness analyses in recent years \[[@CR34]--[@CR39]\]. The clinical outcomes in the present study are consistent with those reported in these financial evaluations. Thus, although this study did not analyze economic effects specifically, it is reasonable to expect that improved IOP control and a 2.43-medication reduction could result in similar benefits as those cited in these cost-effectiveness studies: for example, lower medication costs and provider expenditures, reduced societal burden from visual impairment, improved medication adherence, fewer IOP-related complications, and fewer quality-adjusted life years lost by patients because of poor vision \[[@CR34]--[@CR39]\]. Finally, topical medication usage has long been reported to cause patient-reported ocular surface discomfort and objective ocular surface damage \[[@CR4], [@CR10], [@CR11], [@CR56], [@CR57]\], raising the possibility that decreasing usage may positively impact patients' day-to-day life.

The long-term safety profile was favorable, including no significant intraoperative complications except for one case with slight hyphema that self-resolved without sequelae; postoperative adverse events that were few in number and mild in severity; and no serious ocular adverse events such as those seen with traditional filtering surgery or even some other MIGS devices \[e.g., hypotony, endophthalmitis, corneal complications, myopic shift, stent obstruction, PAS, or choroidal detachment\] \[[@CR13]--[@CR15], [@CR58], [@CR59]\]. Even though 3 years elapsed in this study, patients' visual acuity remained stable, with 100% of eligible eyes retaining CDVA of 20/50 or better through 36 months postoperatively. Two eyes underwent additional glaucoma procedures at 1 month postoperatively due to the need for further IOP lowering, but no other secondary glaucoma surgeries occurred throughout follow-up. This latter observation is notable considering the sizable preoperative disease burden of this cohort, as many of the eyes likely would have undergone filtration surgery if stent implantation were not performed.

Despite the study's strengths, several limitations may be discussed. The study design was non-randomized, unmasked, and consisted of single-surgeon, single-site data. As in nearly all real-world case series, no medication washouts were completed pre- or postoperatively, since these could place patients at undue risk that would not be indicated in standard clinical practice. For similar reasons, there was no control group to act as a counterpoint to the stent-implantation group; however, it is reasonable to treat patients' preoperative numeric data (such as IOP and number of medications) as viable comparators given the objective nature of these measures. This was a real-world, consecutive series, and thus no additional inclusion criteria were used outside of the surgeon's typical prerequisites for undergoing stent surgery. Future reports from this data set could include longer periods of follow-up; stratified outcomes by preoperative medications or prior glaucoma surgery; refractive data; and longitudinal analysis of the C:D ratio, VF, and OCT-measured retinal nerve fiber layer thickness.

Conclusion {#Sec11}
==========

In summary, this real-world prospective cohort of glaucomatous eyes with considerable preoperative disease burden achieved significant and sustained IOP and medication reductions through 36 months after stand-alone iStent *inject* implantation. Favorable long-term safety accompanied these outcomes, yielding a promising benefit-to-risk ratio that supports the viability of this treatment modality in eyes with mild to advanced glaucoma. Since outcomes were observed in a real-world clinical setting, the data can be informative for practicing surgeons and patients making treatment decisions.
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